Effects of exogenous melatonin on clinical and pathological features of a human thyroglobulin-induced experimental autoimmune thyroiditis mouse model

Jiunn-Diann Lin1,2,3, Wen-Fang Fang4, Kam-Tsun Tang5 & Chao-Wen Cheng1,6,7

Melatonin (MLT) plays a significant role in both innate and adaptive immunity, and dysregulation of the MLT signature can modify autoimmune disease phenotypes. In this study, the influence of exogenous MLT administration on regulating autoimmune thyroiditis animal models was evaluated. An experimental autoimmune thyroiditis model was established in MLT-synthesizing (CBA) and MLT-deficient (C57BL/6) mice by immunization with human thyroglobulin (TG), which features thyrotoxicosis, thyrocyte damage, and CD3+ T cell infiltration. In TG-immunized CBA mice, exogenous MLT administration in drinking water (6 μg/ml) enhanced thyroiditis and increased TG-specific splenocyte proliferation but not the anti-thyroglobulin antibody (ATA) titer, while MLT alone caused no significant alteration in thyroid function or histopathology. Meanwhile, MLT administration did not modify thyroid function, the ATA titer, or the thyroid histopathology, but results showed an increase in the splenocyte proliferative capacity in TG-immunized C57BL/6 mice. Collectively, our data showed that early exogenous MLT modified the progression of autoimmune thyroiditis through T cell-driven immunity, and excess MLT worsened the clinical and pathological features.

Melatonin (MLT), is mainly synthesized by the pineal gland, and its secretion is inhibited by light to the retina but enhanced by darkness1. Circulating MLT binds to MT1 and MT2 membrane-bound receptors, and plays a role in regulating circadian and seasonal rhythms, and also works as a free radical scavenger, an antioxidant, and an anticancer adjuvant2,3. In addition, accumulating evidence has shown that the MLT signature acts as a modulator of both innate and acquired immune reactions, and an imbalance of the MLT signature can lead to dysregulated immunity4–7. Because of its prominent immunoregulatory activity, MLT has been extensively explored as a possible therapeutic strategy for multiple autoimmune diseases (AIDs), including systemic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, and rheumatoid arthritis, but responses varied8.

The previous literature linked MLT to the thyroid gland in both in vivo and in vitro experiments, but the results remain controversial. Some studies showed that MLT could suppress the thyroid function in rats, while Gordon et al. reported that chronic MLT administration enhanced thyroid enlargement, increased radiiodine uptake (RAIU), and increased the total thyroid hormone amount without altering the thyroid hormone concentration in the bloodstream of rats9–11. Gesting et al. observed that MLT could inhibit aflatoxin-induced rat thyrocyte apoptosis, which suggested the potential role of MLT in controlling the growth of thyrocytes12. Wright et al. reported that chronic MLT administration enhanced thyroid enlargement, increased radiiodine uptake (RAIU), and increased the total thyroid hormone amount without altering the thyroid hormone concentration in the bloodstream of rats9–11. Gesting et al. observed that MLT could inhibit aflatoxin-induced rat thyrocyte apoptosis, which suggested the potential role of MLT in controlling the growth of thyrocytes12. Wright et al.
disclosed that thyroxine (T4) secretion was reduced in cultures of thyrocytes from different species incubated with MLT production compared to those in a control group. Mogulkoc et al. also showed that MLT could prevent hyperthyroidism-induced tissue damage by reducing oxidative stress. Interestingly, evidence demonstrated that MLT, together with its key synthesizing enzymes, and the MT1 receptor protein exist in the thyroid gland, which further implied that the MLT signature could exert certain biological activities in thyrocytes.

Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are two extreme ends of autoimmune thyroid disease (AITD); in both of these diseases, specific thyroid T-lymphocytes are initially activated against a thyroid autoantigen, followed by induction of either B cell- or cytotoxic T cell-driven immunity, with an ultimate contribution to separate clinical and pathological features. As aforementioned, because MLT exerts immunomodulatory properties and MLT and its key synthesizing enzymes are present in the thyroid gland, it was speculated that the MLT signaling pathway might also participate in the development of AITD or in modifying disease phenotypes. In our published genetic association study, we found that the single-nucleotide polymorphism of MTNR1A, coding the MT1 protein, was associated with a susceptibility to GD and thyroid autoantibody formation, which supports the notion that the MLT signature can influence the occurrence of AITD and clinical features.

In this study, to further explore the effect of the MLT signature on the occurrence of AITD and modulation of disease phenotypes and progression, we utilized an experimental autoimmune thyroiditis (EAT) model by repeatedly injecting human thyroglobulin (TG) in two distinct mouse strains, CBA/CaJNarl (CBA) and C57BL/6J (B6), features with differences in the production of MLT. Subsequently, MLT was exogenously given to the mouse model, and we further evaluated the influence of MLT on the outcome of a TG-immunized mouse model and its potential immunological regulation.

Results

Exogenous MLT treatment enhances plasma T4 and triiodothyronine (T3) levels of TG-induced thyroiditis.

Repeated immunization with TG in CBA mice (TG group) led to the development of thyrotoxicosis, as manifested by increases in plasma T4 and T3 levels (Fig. 1A,B) in the initial phase. At this stage, the positive thyrotoxicosis induction rate was 78.9% (Table 1). Exogenous MLT treatment (MTG group) produced higher plasma T4 and T3 levels compared to the TG group, but without a significant change in the rate of positivity. In addition, there was no significant difference in T3 and T4 levels between the MLT alone group and the control group.

In the recovery phase, the positivity rates of thyrotoxicosis in the TG and MTG groups both declined to 42.9%, and only the MTG group showed a higher plasma T4 level than the control group (Fig. 1C,D). It was noted that treatment with MLT after the initial phase (TGM group) had no significant effects on plasma T4 and T3 levels or
the positivity rate. In the present study, the average intake of MLT-containing water in each MLT-treated mouse was about 6.3 ml/day (≒37.8μg/mice/day).

**Exogenous MLT showed limited effects on plasma ATA and TSHRαb levels with TG-induced thyroiditis.** In order to study the etiology of thyrotoxicosis in TG-induced thyroiditis, plasma TSHRαb titers and ATA levels were analyzed. As shown in Fig. 2, CBA mice in the TG and MTG groups had elevated ATA levels.
compared to those in the control and MLT groups in both the initial and recovery phases. However, there were no differences in ATA titers between the MTG and TG group in either phase (Fig. 2A,B). In addition, TSHRAb levels were not detected in all groups in either the initial or recovery phase (Supplementary Fig. 1A,B).

**Exogenous MLT treatment exacerbated follicle destruction and immune cell infiltration in TG-induced thyroiditis.** Gross pictures of the thyroid glands of the TG, MTG, MLT, and control groups in CBA mice are shown in Supplementary Fig. 2. There was no significant diversity in thyroid size among the four groups. Histological results of thyrocytes of the various groups in CBA mice in the initial and recovery phases are demonstrated in Fig. 3. In the initial phase, TG-immunized mice (Fig. 3A) showed mild thyroid follicle disruption together with minor mononuclear cell infiltration compared to the control group. Interestingly, we observed
extensive thyroid follicle destruction and profound mononuclear cell infiltration in the MTG group (Fig. 3B) compared to the TG group. In the recovery phase, consistent thyroid follicle damage and increased infiltrating mononuclear cells in the MTG group were observed compared to the TG and TGM groups (Fig. 3C–E). In the meantime, neither thyroid follicle destruction nor increased infiltrating cells were observed in MLT-treated alone mice in the recovery phase compared to the control group (Fig. 3F, G).

Exogenous MLT modulated TG-induced thyroiditis predominantly through T cell activation. The potential effects of MLT in modulating immunological features in TG-induced thyroiditis in CBA mice were further evaluated. In the initial phase, splenomegaly was only observed in the MTG group (Fig. 4A), and this phenomenon was reduced in the recovery phase (Fig. 4B). Splenocytes stimulated with TG had increased the cell proliferation index in the TG and MTG groups in the initial phase, but they had declined in the recovery phase (Fig. 5A,B). It was noted that the MTG group showed a higher cell proliferation index than the TG group (Fig. 5A). In addition, infiltration of CD3+ T cells was observed in the TG and MTG groups in both the initial and recovery phases (Fig. 6A–E), but not in the control or MLT-alone groups (Fig. 6F,G). The quantifications of the infiltrated CD3+ T cells of CBA mice were shown in Fig. 6(H,I). In initial phase, mice in TG and MTG groups had higher infiltrated CD3+ T cell numbers than MLT and control groups, while, there was no significant difference between the MTL and control groups and between TG and TGM groups (Fig. 6H). In the recovery phase, TG and MTG groups had higher infiltrated CD3+ T cell numbers than the control group, but there was no significant difference between the control and TGM groups. In addition, there was also no significant difference in infiltrated CD3+ T cell numbers among TG, MTG and TGM groups in recovery phase (Fig. 6I). This evidence indicated the detrimental role of infiltrating T cells in this TG-induced thyrotoxicosis mouse model; in addition, from the splenocyte stimulation assay, we observed that the MTG group exhibited a further increase in activation of T cells compared to the TG group.

**Figure 4.** Spleen weights of CBA mice in the initial (A) and recovery phases (B). Each bar represents the mean and standard error. *p < 0.05; NS, non-significant.
Biochemical results, gross pictures, and histology of thyroid glands in B6 mice. It was reported that endogenous MLT is absent from B6 mice due to a lack of essential enzymes for MLT synthesis21,22. Therefore, B6 mice were also used to examine the effects of MLT in TG-induced thyroiditis. In the initial phase, B6 mice in both the TG and MTG groups had higher T4 levels than those in the control group (Fig. 7A), and the positivity of the thyrotoxicosis induction rate was 83.3% in both groups (Table 2). There were higher ATA levels in both the TG and MTG groups than in the control group, while there was no difference in ATA titers between the TG and MTG groups (Fig. 7B). In addition, no TSHRAb levels were detected in any group (Supplementary Fig. 1C). Splenocytes from both the TG and MTG groups had higher TG-induced cell proliferation indexes, and the MTG group had a higher cell proliferation index than that of the TG group (Fig. 7C). Thyroid sizes in the TG, MTG, and control groups of B6 mice are shown in Supplementary Fig. 2B, and no difference in thyroid sizes among the three groups was apparent. In the histological analysis, mice in the TG and MTG groups showed minor follicle disruption and increased mononuclear infiltration in thyroid histopathology compared to the control group (Fig. 7D–F). However, there was no difference in thyroid pathology observed between the TG and MTG groups of B6 mice.

Discussion
In this study, we created a mouse thyroiditis model by repeated TG injections in different mouse strains, which manifested as thyrotoxicosis, thyroid follicle destruction, and CD3⁺ T cell infiltration. At the same time, we also showed that exogenous MLT administration enhanced TG-induced thyroiditis in both the initial and recovery phases in CBA mice. In the meantime, MLT administration did not alter the serological or pathological features of
thyroiditis in TG-treated B6 mice, which suggests that the influence of MLT in deteriorating thyroiditis is diverse in different strains. Moreover, MLT facilitated the splenocyte proliferation capacity in both strains rather than increased plasma ATA titers after TG immunization, which indicated that MLT exacerbated thyroiditis and thyrotoxicosis in TG-treated mice chiefly by way of T cell-mediated immunity, but not an antibody-driven immune reaction. Our results further confirmed the remarkable influence of the MLT signature in thyroid immune responses, and imply important clinical information that excess MLT intake may alter thyroid functions and aggravate thyroid autoimmunity in the development of AITD patients. Thus, caution should be exercised with the use of MLT in AITD susceptible population.

To clarify the role of MLT signals in AITD progression, we tried to build an EAT model by repeated TG injections according to a protocol proposed by Endo et al. It was well documented that EAT can be established in several mouse strains by injections of a mouse thyroid extract. Interestingly, Valdutiu et al. first observed initial hypothyroidism at 2 weeks but elevated thyroid function at 4 weeks after the initial immunization in several mouse strains, which suggested a possible thyrotoxic phase after injecting mouse TG. Recently, by repeated bovine TG injections in B6 and AKR mice, Endo et al. tried to create an EAT mouse model and found thyroid enlargement, thyroid follicular cell hyperplasia and hypertrophy, elevated thyroid function, the existence of the TSHRAb, and increased thyroid RAIU in week 12 after the first immunization, which was characterized by GD. They suggested that the pathogenesis of autoimmune thyroiditis and GD might be closely related, and the initial event of GD could be derived from autoimmune thyroiditis. In the present study, we induced thyrotoxicosis in B6 and CBA mice. However, we were unable to demonstrate the presence of the TSHRAb in the bloodstream, and importantly, we observed thyrocyte destruction and increased infiltrating inflammatory mononuclear cells with CD3, rather than thyrocyte hyperplasia and hypertrophy by histopathology in both strains, which strongly suggested autoimmune thyroiditis in essence. Moreover, in CBA mice, we observed a significant decline in plasma T4 levels from the initial phase to the recovery phase (p = 0.010, data not shown), which further implied that thyroid function in a TG-induced mouse model cannot be maintained like in a GD model. Finally, the actual mechanism of the conflicting results between ours and Endo et al. is unknown, and might be attributed to different adjuvant administration routes and sources of TG for immunization. In addition, the TSHR stimulating activity measurement by cyclic AMP production as pervious work, was not determined in the present study. It is also possible that some of these immunized mice with low TSHRAb titer might have high TSHR stimulating...
activity, and subsequently activate thyrocytes, and presented like GD. Further molecular-based studies of the detailed pathogenesis are needed.

In the present study, we further assessed the impacts of MLT administration on inducing and promoting disease progression in a TG-immunization mouse model. After MLT was given 1 week prior to the TG immunization, we found that there was no difference in the positive induction rates between the TG and MTG groups in the initial and late phases. However, we found deteriorated thyroid function and more-extensive thyrocyte

Figure 7. Thyroid functions (A), anti-human thyroglobulin antibody titer (B), cell proliferation index (C), and histology (D–F) in B6 mice. (D) TG-immunized mice showing mild thyroid follicle disruption and mononuclear cell infiltrations in the initial phase (400x). (E) MTG group showing mild thyroid follicular destruction and mononuclear cell infiltration in the initial phase (400x). (F) Normal thyroid tissue of B6 mice (400x). T4, thyroxine; Cell proliferation index, under stimulation with 10 μg/ml human thyroglobulin. Each bar represents the mean and standard error. *p < 0.05, **p < 0.01; ***p < 0.001.
destruction in the MLT treated TG-immunized CBA strain, and the facilitating effect of MLT in TG-immunized CBA mice was still present in the recovery phase according to the biochemical and histopathological analyses. At the same time, we also observed that MLT augmented the splenocyte TG-specific cell proliferation capacity, but not the plasma ATA titer, which suggested that initial MLT administration could facilitate thyrotoxicosis chiefly by operating the T cell-mediated immune reaction rather than antibody-driven immunity in the early stage in the TG-immunized CBA strain. Our results were compatible with observations from other reports, which demonstrated that chronic MLT administration can enhance Th1 cytokine production and promote Th1 immunity polarization. Our results were also in line with the findings conducted by Baltaci et al., which showed that MLT could play a crucial role in the cell-mediated immunity in vivo. In contrast, MLT administration after completing four doses of TG immunization did not alter thyroid function, ATA titers, splenocyte cell proliferation capacities, or thyroid histopathology compared to those of the TG-immunized alone group of CBA mice, which indicated that late MLT administration might not significantly contribute to the regulation of thyroid function or thyroid immunity in a full-blown TG-immunized CBA mouse model. This evidence suggests that MLT contributed to the process of the progression of thyroiditis, but showed slighter effects on modifying the established disease status. Interestingly, we also found that there was no significant change in thyroid function (T3, T4), thyroid histopathology, or the splenocyte cell proliferation index between the MLT and control groups of CBA mice, which suggested that MLT alone might play a very limited role in thyroid function and the induction of de novo thyroid autoimmunity in the normal thyroid.

Interestingly, the influence of enhancing thyrotoxicosis and thyrocyte damage by MLT administration was not observed in B6 mice, while the MLT-promoting TG-specific T-cell proliferation ability was preserved. These findings imply that MLT exhibited a minor effect on altering thyroid autoimmunity in TG-immunized B6 mice compared to TG-immunized CBA mice. Variations in thyroid function between CBA and B6 mice may be attributed to distinct strain-specific immune reactions to the antigen or immunoregulator. Moreover, CBA mice are known to be able to synthesize MLT, while MLT is absent from B6 mice due to a lack of essential enzymes for MLT synthesis. Exogenous MLT administration could lead to excessive MLT accumulation in CBA mice, but not in the B6 strain, which might further contribute to the profound thyroid dysfunction and immune dysregulation in TG-immunized CBA mice compared to B6 mice. In other words, higher dose of MLT might be required to demonstrate comparable effect in B6 mice than in CBA mice.

To our best knowledge, this is the first study to show that MLT administration increases plasma thyroid hormone levels and enhances thyrocyte destruction and the T-cell proliferation capacity in a TG-immunized thyroiditis mouse model. The combined results of the animal and our previous genetic-association studies highlight how the MLT signaling pathway plays a considerable role in the development and modulation ofAITD. However, we should point out certain limitations of the study. First, the RAIU of the mice thyroid gland were not quantified in the study, which could have further clarified the presence of thyroiditis in the mice model. Second, the daily exogenous MLT uptake on average was about 37.8 μg/mice in the present study. The results might differ with other concentrations of MLT treatment; further well-designed studies with different dosages of MLT to explore the responses of MLT in HT models are required. Finally, compared to the "typical form of HT", the thyrotoxic phase of thyroiditis as in the present study is less frequently seen in clinical settings. Our future plan is to create a classical HT model to clarify the role of MLT in the progression of HT.

In conclusion, the presence of increasing MLT enhanced the T cell immune response and early exogenous MLT administration exacerbated the clinical and pathological features of TG-induced thyroiditis.

### Materials and Methods

**Immunization of mice.** Briefly, 42 female B6 and 85 CBA mice were purchased from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). All mice were 12–14 weeks old at the beginning of the experiments. TG, purchased from Calbiochem (La Jolla, CA), was emulsified with the same volume of complete Freund’s adjuvant (CFA, Wako Chemical, Tokyo, Japan) and then 50 μl of an emulsion (25 μg TG/mouse) was injected into the soleus muscle of each mouse at week 0. Two weeks later, TG was emulsified with the same volume of incomplete Freund’s adjuvant (ICFA, Wako Chemical) and was injected once every 2 weeks with a total of three doses (at weeks 2, 4, and 6). Saline emulsified with the same volume of either CFA (at week 0) or ICFA (at week 2, 4, and 6) was injected into the control group.

### Table 2. Responses after human thyroglobulin immunization in different groups of C57BL6 mice in the initial and recovery phases. Positivity is defined as mice with a T4 level of > mean + 2X standard deviations of the T4 level in control mice.

|                | Positive rate | Negative rate | p value |
|----------------|--------------|---------------|---------|
|                | N (%)        | N (%)         |         |
| **Initial phase** |              |               |         |
| TG             | 5 (83.3%)    | 1 (16.7%)     | 1.000   |
| MTG            | 5 (83.3%)    | 1 (16.7%)     |         |
| **Recovery phase** |              |               |         |
| TG             | 8 (100%)     | 0 (0%)        |         |
| MTG            | 8 (100%)     | 0 (0%)        |         |
| TGM            | 8 (100%)     | 0 (0%)        |         |
The different treatment groups were defined as follows: TG group, TG immunization without MLT treatment; MTG group: TG immunization with MLT treatment, MLT administration 1 week before the first TG immunization; MLT group: treated as the control group, but MLT was administered 1 week before the first CFA injection; TGM, MLT administration began in the initial phase. MLT (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in daily drinking water at a concentration of $6\,\mu g/ml$ in a water bottle protected against light in every cage. The daily water intake in each group did not differ significantly during the entire course of the experiment. Mice were sacrificed at either 8 (initial phase) or 13–14 weeks (recovery phase). The immunizations and treatments in each group were shown in Fig. 8. The protocol and procedures employed were ethically reviewed and approved by the Institutional Animal Care and Use Committee of Taipei Medical University and all methods were performed in accordance with the relevant guidelines and regulations.

**Total T4 and Total T3 measurements (enzyme-linked immunosorbent assay (ELISA)).** The microplate provided in the ELISA kit was pre-coated with an antibody specific to T4 or T3 (CUSABIO Biotech, Wuhan, China). A standard or sample was added to the appropriate microtiter plate wells with biotin-conjugated T4/T3. A competitive inhibition reaction was launched between T4/T3 and biotin-conjugated T4/T3 with the pre-coated antibody specific to T4/T3. After washing, avidin-conjugated horseradish peroxidase was added to the wells. A substrate solution was added to the wells, and the color was allowed to develop in contrast to the amount of T4/T3 in the sample. Color development was stopped, and the intensity of the color was measured at OD 450 nm.

**ATA measurement.** Plasma samples from each group were collected at 8 weeks after the first TG immunization. ELISA plates were coated with TG (1 mg/ml in carbonate buffer) and blocked with 5% bovine serum albumin (BSA). Following extensive washing, mouse sera [diluted 1:200 in Tris-buffered saline] was added to the wells. Bound antibodies were detected using anti-mouse immunoglobulin G (IgG) rabbit serum conjugated to alkaline phosphatase (Jackson Immuno-Research, West Grove, PA), and the intensity of the color in the plates was measured at OD 450 nm.

**Thyroid-stimulating hormone (TSH) receptor (TSHR) antibody (TSHRAb).** Serum TSHRAb concentrations were quantified by an ELISA method using a commercial TSH receptor-coated plate (RSR Ltd, Cardiff, UK). A competitive inhibition reaction was initiated between the TSHRAb and M22-peroxidase with the pre-coated TSHR. The greater the amount of the TSHRAb in a sample, the less antibody that was bound by the biotin-conjugated TSHRAb. The tetramethylbenzidine (TMB) solution was added to the wells, and the color developed in contrast to the concentration of the TSHRAb in the sample. Color formation was discontinued, and the intensity of the color was measured at OD 450 nm on an ELISA reader. The results of individual samples were obtained after the negative control was assigned to a value of 0.1 $\mu g/L$, and a standard curve was created.

**Immunohistochemistry (IHC).** IHC staining of thyroid tissues was performed using labeled streptavidin-biotin (LSAB 2 kit; DAKO, Carpinteria, CA, USA), as previously described. Briefly, 3-µm paraffin sections were prepared on silane-coated microslides and deparaffinized in a xylene solution (Paraclear; Earthsafe Tech, Belle Mead, NJ) for 15 min. After rehydration in a graded (95%, 80%, and 75%) alcohol series,
sections were microwaved in 0.01 M sodium citrate buffer for 15 min. Sections were blocked using TBST containing 2% BSA for 30 min and then incubated at 4°C overnight with a 1:100 dilution of CD3 (GTc16667, Genetax, San Antonio, TX). After washing, sections were incubated with an anti-goat IgG-biotin conjugate (Santa Cruz Biotechnology, Santa Cruz, CA) for 60 min, followed by streptavidin-horseradish peroxidase (EnVision DAB kit, DAKO) for 20 min. To determine peroxidase activity, sections were incubated with 3,3-diaminobenzidine (DAB, DAKO) for 10 min in the dark. Finally, sections were counterstained with hematoxylin-eosin for histological examination. The average numbers of infiltrated CD3 positive cell were quantified from five randomly non-overlapping 200X power field in each tissue samples.

**Splenocyte proliferative assay.** The spleens of immunized mice were meshed into single cell suspensions and cultured in RPMI medium containing 5% fetal bovine serum (FBS). Splenocytes were seeded at 2 × 10⁶ cells/ml and 200 μl/well in a 96-well flat-bottom plate and stimulated with 0, 1, and 10 μg/ml of TG. Cell proliferation was further assessed by adding a mixture of the tetrzolium salt, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carb oxymethoxyphenyl)-2H-tetrazolium (MTS) and phenazine methosulphate, and the intensity of the color in the plates was measured at OD 490 nm.

**Statistical analysis.** SPSS vers. 13.0 for Windows (SPSS, Chicago, IL, USA) was used for all statistical analyses. Quantitative values are shown as the mean ± standard error (SE). A one-way analysis of variance (ANOVA) was used to compare differences in clinical parameters among the different groups. The LSD test was used for post-hoc examinations. The positivity of thyrotoxicosis induction was defined as previously described, mouse with a plasma T4 value greater than the mean + 2 X standard deviations of T4 obtained from the control group. All statistical tests were two-sided, and a p value of < 0.05 was considered significant.

**References**

1. Nunnari, G. et al. Reduction of serum melatonin levels in HIV-1-infected individuals’ parallel disease progression: correlation with serum interleukin-12 levels. *Infection* 31, 379–382 (2003).
2. Reiter, R. J. The melatonin rhythm: both a clock and a calendar. *Experientia* 49, 654–664 (1993).
3. Maldonado, M. D. et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. *J Pineal Res* 42, 1–11 (2007).
4. Miller, S. C., Pandi-Perumal, S. R., Esquifino, A. I., Cardinali, D. P. & Maestroni, G. J. The role of melatonin in immunoenhancement: potential application in cancer. *Int J Exp Pathol* 87, 81–87 (2006).
5. Cernysiov, V., Gerasimcik, N., Mauricas, M. & Girkontaite, I. Regulation of T-cell-independent and T-cell-dependent antibody production by circadian rhythm and melatonin. *Int Immunol* 22, 25–34 (2010).
6. Rodríguez, I. R., Mazurak, K., Schoen, T. J. & Chader, G. J. Structural analysis of the human hydroxyindole-O-methyltransferase gene. *Presence of two distinct promoters*. *J Biol Chem* 269, 31969–31977 (1994).
7. Polli, C., Caroleo, M. C., Nistico, G. & Doria, G. Melatonin increases antigen presentation and amplifies specific and non-specific signals for T-cell proliferation. *Int Immunopharmacol* 15, 463–468 (1993).
8. Lin, G. J. et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. *Int J Mol Sci* 14, 11742–11766 (2013).
9. Gordon, J., Morley, J. E. & Fershman, J. M. Melatonin and the thyroid. *Horm Metab Res* 12, 71–73 (1980).
10. Ishibashi, T., Hahn, D. W., Srivastava, L., Kumaresan, P. & Turner, C. W. Effect of pinealectomy and melatonin on feed consumption and thyroid hormone secretion rate. *Proc Soc Exp Biol Med* 122, 644–647 (1966).
11. Bagchi et al. *Modifications of thyroid activity by melatonin*. *Experientia* 19, 15–17 (1963).
12. Baltaci, A. K., Mogulkoc, R., Kul, A., Bediz, C. S. & Ugur, A. Opposite effects of zinc and melatonin on thyroid hormones in rats. *Toxicology* 195, 69–75 (2004).
13. Baltaci, A. K., Mogulkoc, R., Bediz, C. S., Kul, A. & Ugur, A. Pinealectomy and zinc deficiency have opposite effects on thyroid hormones in rats. *Endocrine Research* 29, 473–481 (2003).
14. Gesing, A., Jagiela, J. & Lewinski, A. Effects of melatonin on the process of apoptosis in rat thyroid follicular cells. *Neuro Endocrinol Lett* 27, 81–84 (2006).
15. Wright, M. L., Pikula, A., Babski, A. M., Labieniec, R. F. & Wolan, R. B. Effect of melatonin on the response of the thyroid to thyrotropin stimulation in vitro. *Gen Comp Endocrinol* 108, 298–305 (1997).
16. Mogulkoc, R., Baltaci, A. K., Oztekin, E., Aydin, L. & Sivrikaya, A. Melatonin prevents oxidant damage in various tissues of rats with hyperthyroidism. *Life Sci* 79, 311–315 (2006).
17. Garcia-Maurino, S., Pozo, D., Carrillo-Vico, A., Calvo, J. R. & Guerrero, J. M. Melatonin activates Th1 lymphocytes by increasing IL-12 production. *Life Sci* 65, 2143–2150 (1999).
18. Carrillo-Vico, A. et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. *J Clin Endocrinol Metab* 90, 992–1000 (2005).
19. Baltaci, A. K., Bediz, C. S., Mogulkoc, R., Kurtoglu, E. & Pelak, A. Effect of zinc and melatonin supplementation on cellular immunity in rats with toxoplasmosis. *Biological trace element research* 96, 237–245 (2003).
30. Baltaci, A. K., Mogulkoc, R., Bediz, C. S. & Pekel, A. Effects of zinc deficiency and pinealectomy on cellular immunity in rats infected with Toxoplasma gondii. *Biological trace element research* **104**, 47–56 (2005).

31. Chwelatiuk, E., Włodowiski, T., Krasowska, A. & Bonda, E. The effect of orally administered melatonin on tissue accumulation and toxicity of cadmium in mice. *J Trace Elem Med Biol* **19**, 259–265 (2006).

32. Jiang, X. *et al.* STAT6 deficiency ameliorates Graves’ disease severity by suppressing thyroid epithelial cell hyperplasia. *Cell Death Dis* **7**, e2506 (2016).

33. Won, J. G. *et al.* Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). *Clin Endocrinol (Oxf)* **65**, 566–578 (2006).

34. Won, J. G. *et al.* Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. *Metabolism* **52**, 1320–1329 (2003).

35. Misharin, A. V., Nagayama, Y., Aliesky, H. A., Rapoport, B. & McLachlan, S. M. Studies in mice deficient for the autoimmune regulator (Aire) and transgenic for the thyrotropin receptor reveal a role for Aire in tolerance for thyroid autoantigens. *Endocrinology* **150**, 2948–2956 (2009).

**Acknowledgements**

This work was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 104-2314-B-038-048 and MOST 106-2314-B-038-059), and was partly supported by a grant from Taipei Medical University and Shuang-Ho Hospital (106TMU-SHH-15).

**Author Contributions**

Wen-Fang Fang, Jiunn-Diann Lin and Chao-Wen Cheng collected data. Jiunn-Diann Lin and Chao-Wen Cheng researched the data and contributed to the discussion. Jiunn-Diann Lin and Chao-Wen Cheng wrote the manuscript. Kam-Tsun Tang and Chao-Wen Cheng reviewed and edited the manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-42442-0.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

© The Author(s) 2019